Page 18 - 《中国药房》2026年2期

Lancet，2011，377（9763）：393-402. penia[J]. Drugs，2021，81（16）：1905-1913.
[12] ZHANG J X，LIANG Y，AI Y，et al. Eltrombopag versus [24] LABANCA C，VIGNA E，MARTINO E A，et al. Avatrom‐
romiplostim in treatment of adult patients with immune bopag for the treatment of immune thrombocytopenia[J].
thrombocytopenia：a systematic review incorporating an Eur J Haematol，2025，114（5）：733-746.
indirect-comparison meta-analysis[J]. PLoS One，2018，13 [25] MEI H，LIU X F，LI Y，et al. Dose tapering to withdrawal
（6）：e0198504. stage and long-term efficacy and safety of hetrombopag
[13] MEI H，LIU X F，LI Y，et al. A multicenter，randomized for the treatment of immune thrombocytopenia：results
phase Ⅲ trial of hetrombopag：a novel thrombopoietin re‐ from an open-label extension study[J]. J Thromb Hae‐
ceptor agonist for the treatment of immune thrombocyto‐ most，2022，20（3）：716-728.
penia[J]. J Hematol Oncol，2021，14（1）：37. [26] WANG Z L，CHEN X G，LI A W，et al. Effect of food on
[14] TERRAULT N，CHEN Y C，IZUMI N，et al. Avatrom‐ the pharmacokinetic and pharmacodynamic profiles of
bopag before procedures reduces need for platelet transfu‐ hetrombopag in healthy volunteers[J]. Clin Ther，2020，42
sion in patients with chronic liver disease and thrombocy‐ （12）：2280-2288.
topenia[J]. Gastroenterology，2018，155（3）：705-718. [27] DICKINSON M，CHERIF H，FENAUX P，et al. Azaciti‐
[15] POORDAD F，TERRAULT N A，ALKHOURI N，et al. dine with or without eltrombopag for first-line treatment
Avatrombopag，an alternate treatment option to reduce of intermediate- or high-risk MDS with thrombocytopenia
platelet transfusions in patients with thrombocytopenia [J]. Blood，2018，132（25）：2629-2638.
and chronic liver disease-integrated analyses of 2 phase 3 [28] BUSSEL J B，SOFF G，BALDUZZI A，et al. A review of
studies[J]. Int J Hepatol，2020，2020：5421632. romiplostim mechanism of action and clinical applicability
[16] HIDAKA H，KUROSAKI M，TANAKA H，et al. Lu‐ [J]. Drug Des Devel Ther，2021，15：2243-2268.
sutrombopag reduces need for platelet transfusion in pa‐ [29] ASLANIS V，ZHANG J P，LOMELI B，et al. Effect of
tients with thrombocytopenia undergoing invasive proce‐ cyclosporine coadministration on the pharmacokinetics of
dures[J]. Clin Gastroenterol Hepatol，2019，17（6）：1192- eltrombopag in healthy volunteers[J]. Cancer Chemother
1200. Pharmacol，2018，82（5）：847-855.
[17] PECK-RADOSAVLJEVIC M，SIMON K，IACOBELLIS [30] ALLRED A J，BOWEN C J，PARK J W，et al. Eltrom‐
A，et al. Lusutrombopag for the treatment of thrombocyto‐ bopag increases plasma rosuvastatin exposure in healthy
penia in patients with chronic liver disease undergoing volunteers[J]. Br J Clin Pharmacol，2011，72（2）：321-329.
[31] JENKINS J M，WILLIAMS D，DENG Y L，et al. Phase 1
invasive procedures（L-PLUS 2）[J]. Hepatology，2019，70
（4）：1336-1348. clinical study of eltrombopag，an oral，nonpeptide throm‐
bopoietin receptor agonist[J]. Blood，2007，109（11）：
[18] MARANO M，SERAFINELLI J，CAIROLI S，et al.
Eltrombopag-induced acute liver failure in a pediatric pa‐ 4739-4741.
[32] NOMOTO M，ZAMORA C A，SCHUCK E，et al. Pharma‐
tient：a pharmacokinetic and pharmacogenetic analysis[J].
Ther Drug Monit，2018，40（4）：386-388. cokinetic/pharmacodynamic drug-drug interactions of
avatrombopag when co-administered with dual or selec‐
[19] COOPER N，ALTOMARE I，THOMAS M R，et al.
Assessment of thrombotic risk during long-term treatment tive CYP2C9 and CYP3A interacting drugs[J]. Br J Clin
Pharmacol，2018，84（5）：952-960.
of immune thrombocytopenia with fostamatinib[J]. Ther
Adv Hematol，2021，12：20406207211010875. [33] KATSUBE T，INOUE Y，FUKUHARA T，et al. Evalua‐
tion of drug-drug interaction of lusutrombopag，a thrombo‐
[20] GHANIMA W，COOPER N，RODEGHIERO F，et al.
Thrombopoietin receptor agonists：ten years later[J]. Hae‐ poietin receptor agonist，via metabolic enzymes and trans‐
porters[J]. Eur J Clin Pharmacol，2020，76（12）：1659-
matologica，2019，104（6）：1112-1123.
[21] CINES D B，GERNSHEIMER T，WASSER J，et al. Inte‐ 1665.
[34] GRAINGER J，BUSSEL J，TARANTINO M，et al. A
grated analysis of long-term safety in patients with
chronic immune thrombocytopaenia（ITP）treated with the single-arm，long-term efficacy and safety study of subcuta‐
neous romiplostim in children with immune thrombocyto‐
thrombopoietin（TPO）receptor agonist romiplostim[J]. Int penia[J]. Blood Adv，2023，7（3）：396-405.
J Hematol，2015，102（3）：259-270.
[35] XIE C Y，ZHAO H J，BAO X B，et al. Pharmacological
[22] JURCZAK W，CHOJNOWSKI K，MAYER J，et al. Phase characterization of hetrombopag，a novel orally active hu‐
3 randomised study of avatrombopag，a novel thrombo-
man thrombopoietin receptor agonist[J]. J Cell Mol Med，
poietin receptor agonist for the treatment of chronic
2018，22（11）：5367-5377.
immune thrombocytopenia[J]. Br J Haematol，2018，183
（收稿日期：2025-08-01 修回日期：2025-12-18）
（3）：479-490.
（编辑：舒安琴）
[23] MARKHAM A. Avatrombopag：a review in thrombocyto‐

· 148 · China Pharmacy 2026 Vol. 37 No. 2 中国药房 2026年第37卷第2期